A hybrid discrete-continuum model of immune responses to SARS-CoV-2 infection in the lung alveolar region, with a focus on interferon induced innate responseArticle Published on 2022-12-212022-11-15 Journal: Journal of theoretical biology [Category] COVID19(2023년), SARS, 변종, 치료제, [키워드] adaptive alveolar alveolar cells antibodies antibody antibody concentration baseline Cell cell death Cellular automaton COVID-19 develop diffusion domain Efficacy Future Gas exchange healthy human lung Immune cell immune protection immune response Immunity infected cell Infection initial Innate innate immune Innate immunity innate response Interaction interferon interferons lung alveolar maintain manuscript mechanism Model multiple mechanism outcome Pneumonia produced profiles progression Result RNA copy SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 variant simulations. Spread Strains submitted switching T cells the SARS-CoV-2 virus two-dimensional type I Viral load virion virions [DOI] 10.1016/j.jtbi.2022.111293 PMC 바로가기
The Third dose of CoronVac vaccination induces broad and potent adaptive immune responses that recognize SARS-CoV-2 Delta and Omicron variantsCoronVac 백신 3차 접종은 SARS-CoV-2 Delta 및 Omicron 변이체를 인식하는 광범위하고 강력한 적응 면역 반응 유도Article Published on 2022-12-012022-09-11 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 진단, 치료기술, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 adaptive Adaptive immune response B cell B cells boost booster booster dose booster vaccination CD4 CD8 Cell circulating comparable contagious CoronaVac coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 vaccine Delta demonstrated detectable domain dose effective elevated elicited fold follicular healthy subject helper T cell Humoral immunity IgA responses immune responses Inactivated vaccine individual induce memory B memory B cell memory B cells neutralization neutralization activities neutralization activity neutralization. neutralizing activities omicron Omicron variants peaked predominant preserved Protein RBD receiving recognize reduced remained respiratory response SARS-CoV-2 SARS-CoV-2 delta SARS-CoV-2 variant significantly increased spike-specific IgG strain subpopulations sustained T cell T cell responses T cells T cells response vaccination variant variants VOCs [DOI] 10.1080/22221751.2022.2081614 PMC 바로가기 [Article Type] Article
A six-month study of anti-SARS-CoV-2 BNT162b2 mRNA vaccination: A comparative analysis of essential trace elements and anti-RBD IgG sera levelsArticle Published on 2022-12-012022-11-15 Journal: Journal of trace elements in medicine and biology [Category] COVID19(2023년), SARS, 진단, 치료기술, [키워드] (Post)vaccinal immunity adaptive Analysis analyzed Anti-RBD IgG anti-SARS-CoV-2 anti-SARS-CoV-2 IgG Antibody detection Antibody titers association biochemical BNT162b2 mRNA BNT162b2 mRNA vaccine changes in Concentration Cu Effect elevated Essential Essential trace elements expressed female follow-up period glycoprotein healthy HEK-293 human serum IgG antibody Immunity immunization investigated mRNA vaccine mRNA vaccine. not affected observation period produced producing Protein purified RBD Receptor binding domain remained SARS-CoV-2 sera serum specific IgG antibody spike T cells Total Trace element vaccination Vaccine Volunteer women Zn [DOI] 10.1016/j.jtemb.2022.127079 PMC 바로가기
Whole-genome sequence analysis reveals the circulation of multiple SARS-CoV-2 variants of concern in Nairobi and neighboring counties, Kenya between March and July 2021Article Published on 2022-11-082022-11-16 Journal: Virology Journal [Category] SARS, 변종, [키워드] adaptive analysis analyzed B.1.1.7 B.1.351 B.1.617.2 Beta bioinformatics circulation community transmission comparison Coronaviruses COVID-19 COVID-19 cases Delta Epidemics genome sequence increase in Kenya Lineage majority Mutation Neutralizing antibodies Oxford Nanopore Technologies Phylogenetic Prevalence protocol reduced Region regions reveal RNA RT-PCR SAR-CoV-2 SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 strain SARS-CoV-2 variant SARS-CoV-2. sequence Sequence analysis Sequencing Spread Strains study period the SARS-CoV-2 variant virulence virus virus transmissibility VoC was performed [DOI] 10.1186/s12985-022-01895-y PMC 바로가기
Phase II/III trial of hyperimmune anti-COVID-19 intravenous immunoglobulin (C-IVIG) therapy in severe COVID-19 patients: study protocol for a randomized controlled trialArticle Published on 2022-11-082022-11-16 Journal: Trials [Category] SARS, 변종, [키워드] adaptive anti-COVID-19 IVIG antivirals clinical evidence clinical trial collected convalescent convalescent plasma COVID-19 cumulative death Efficacy eligibility criteria evaluate Health hyperimmune immunization immunomodulators intravenous Intravenous immunoglobulin low dose monoclonal antibodies Neutralizing non-specific novel Novel coronavirus outcome Passive passive immunization Patient phase Pneumonia polyclonal polyclonal antibodies Pooled convalescent plasma Potential treatment Randomized Randomized controlled trial receive Recovered COVID-19 patients reported SARS CoV-2 SARS CoV-2. SARS-CoV-2 sealed Secondary outcomes severe COVID-19 severe COVID-19 patient severe COVID-19 patients Standard of care Steroids Study protocol therapeutic option therapy treat Treatment Trial variant variants of concern virus virus particles World Health Organization [DOI] 10.1186/s13063-022-06860-2 PMC 바로가기
Reconstructed Genome-Scale Metabolic Model Characterizes Adaptive Metabolic Flux Changes in Peripheral Blood Mononuclear Cells in Severe COVID-19 PatientsArticle Published on 2022-10-172022-11-15 Journal: International Journal of Molecular Sciences [Category] COVID19(2023년), SARS, 유전자 메커니즘, 치료제, [키워드] acute respiratory syndrome adaptive aerobic Analysis anti-inflammatory effect antiviral drugs biogenesis caused change changes in Coronavirus disease 2019 Coronavirus-2 COVID-19 differentially expressed enzyme FASN fatty flux Glycolysis Health Immune cell Inflammation Inflammatory lipids mechanism metabolic metabolic model metabolism metabolism-directed therapy. metabolites Model mononuclear cell nucleotide oxidative phosphorylation pathogenic PBMC PBMCs peripheral Peripheral blood potential therapeutic targets provide reaction reconstructed Regulation responsible retinol SARS-CoV-2 severe COVID-19 patients SLC2A3 therapy Transcriptome Treatment Vitamin [DOI] 10.3390/ijms232012400 PMC 바로가기
SARS-CoV-2 in immunocompromised individualsArticle Published on 2022-10-112022-11-15 Journal: Immunity [Category] COVID19(2023년), SARS, 치료제, [키워드] adaptive anti-CD20 antiviral immune response B cell Cancer clearance Combination COVID-19 COVID-19 pandemic Critical Hematologic malignancy Immunity Immunocompromised immunocompromised individual immunologically immunosuppressive IMPROVE increased risk individual Infection Inflammation information limit morbidity and mortality populations provided SARS-CoV-2 T cell therapy Treatment treatment strategy underlying conditions understanding vaccination vaccination. viral infection virus [DOI] 10.1016/j.immuni.2022.09.006 PMC 바로가기
Arylcoumarin perturbs SARS-CoV-2 pathogenesis by targeting the S-protein/ACE2 interactionArticle Published on 2022-10-112022-11-16 Journal: Scientific Reports [Category] COVID19(2023년), SARS, 변종, [키워드] ACE2 adaptive Analysis antibody binding affinity binding site convalescent coumarin COVID-19 D614G death derivative develop docking drug human Angiotensin-converting enzyme human host in vitro in vivo Infection inhibitor inhibitors Interaction lack molecular molecular docking analysis Mutation N501Y new SARS-CoV-2 NF1 oxygen protein complex protocol rapid increase receptor Reinfection required S-protein SARS-CoV-2 SARS-CoV-2 pathogenesis SARS-CoV-2 spike glycoprotein second wave Spike proteins Treatment vaccinated individuals vaccination variant variants viral genome [DOI] 10.1038/s41598-022-20759-7 PMC 바로가기
Adaptive immunity to SARS-CoV-2 infection: A systematic reviewArticle Published on 2022-10-102022-11-15 Journal: Frontiers in Immunology [Category] COVID19(2023년), SARS, 바이오마커, [키워드] acute respiratory syndrome adaptive Adaptive immunity addressed Alpha Antigen article B cell Biomarker case-control study caused CD4+ T cell CD8+ CD8+ T lymphocytes Cell cell types Characteristics clinical benefits Cohort studies coronavirus coronavirus disease Course COVID-19 Critically ill Critically ill patient cross-sectional CXCL9 Cytokines database disease English Evidence experimental evidence follicular HLA-DR humoral Humoral immunity IL-10 IL-13 IL-15 IL-17 IL-1α IL-2 IL-21 IL-22 IL-23 IL-4 IL-5 IL-7 immune system Immunity immunity. immunological Immunological memory immunopathological in vitro assays individuals inflammatory mediator involved leukocyte Ligand lymphocyte marker mild case Necrosis poor prognosis predominant produced programmed cell death progression Protein Regulatory T cell responsible SARS-CoV-2 SARS-COV-2 infection SciELO secretion severity Spanish subpopulation systematic review T helper T helper cell T lymphocyte T-cell Response Tfh TGF-β Th1 Th17 Th2 the antibody the disease TNF-α Treg tumor growth Vaccine variable [DOI] 10.3389/fimmu.2022.1001198 PMC 바로가기
A multinational, phase 2, randomised, adaptive protocol to evaluate immunogenicity and reactogenicity of different COVID-19 vaccines in adults ≥75 already vaccinated against SARS-CoV-2 (EU-COVAT-1-AGED): a trial conducted within the VACCELERATE networkArticle Published on 2022-10-082022-11-15 Journal: Trials [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] ≥75 years. adaptive addition advanced age age Analysis Antibody titre benefit BNT162b2 BNT162b2 (Comirnaty®) booster booster dose changes in Clinical course collected concern conducted COVID-19 COVID-19 pandemic COVID-19 vaccination COVID-19 vaccine dose Endpoint enzyme-linked immunosorbent evaluate exploratory fourth dose humoral immune response immunosenescence include individual initial Intervention mRNA-1273 mRNA-1273 (Spikevax®) multicentre neutralising neutralising antibody titre Older Part Patient performed phase phase II primary endpoint protocol qPCR Quantitative randomisation randomised randomised controlled reactogenicity Research risk factor SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 vaccine secondary subgroup T cell response the primary endpoint Trial triggered vaccination Vaccine vaccine-induced immune response variants variants of concern VoC wild-type wild-type virus [DOI] 10.1186/s13063-022-06791-y PMC 바로가기